The human brain has long been regarded as one of the most versatile parts of the body due to neuroplasticity. This is basically the concept where people can change the properties of their gray matter by introducing particular stimuli. In recent research papers, scientists are seeing indications that meditating can lead to a brain that is decades younger than the body and a heightened level of selflessness.
As Futurism notes, there have been numerous studies related to the effects of meditation on neuroplasticity. One of these is the Johns Hopkins School of Public Health study that found how meditation can help decrease anxiety and depression just as well as drugs.
There are also studies that note how meditation can affect certain parts of the brain in order to make them seem younger. There were even cases where patients 50 years of age had similar gray matter levels to those 25 years their junior. One of the biggest benefits to this kind of result includes the prevention of dementia or some other type of neurological degradation.
With regards to the psychological effects of meditation, it has long been accepted that the practice is meant to encourage peace of mind. However, a Yale study also discovered that it can make people less selfish. The study also found that it helped to increase concentration as well as to be more considerate of others.
Even overcoming smoking addiction has been the subject of research involving meditation, with some cases reporting success rates of 60 percent. The same goes for cases where self-control is an issue, so it basically applies to pretty much any kind of addiction.
All in all, numerous scientific literature are now suggesting that meditation is a solution to many of the problems that people often address via drugs or some other form of addictive activity. Heck, it can even supplant exercise, though, it’s always best to combine both.


FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez 



